Evidence map›Paper›PMID 32364634›Full record

ArticlePhytotherapy research : PTR2020

Neferine, an alkaloid from lotus seed embryo targets HeLa and SiHa cervical cancer cells via pro-oxidant anticancer mechanism.

Subramanyam Dasari, Velavan Bakthavachalam, Somaiah Chinnapaka, Reshmii Venkatesan, Angela L P A Samy, Gnanasekar Munirathinam

Open access · greenAbstract read
In one paragraph

Article in Phytotherapy research : PTR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Lotus seedFrontiers in chemistry · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. The impact of vitamin D on cancer: A mini review.The Journal of steroid biochemistry and molecular biology · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Lotus (Cancers · 2022
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Subramanyam DasariDepartment of Biomedical Sciences, College of Medicine, University of Illinois, Rockford, Illinois, USA.
Velavan BakthavachalamDepartment of Biomedical Sciences, College of Medicine, University of Illinois, Rockford, Illinois, USA.
Somaiah ChinnapakaDepartment of Biomedical Sciences, College of Medicine, University of Illinois, Rockford, Illinois, USA.
Reshmii VenkatesanDepartment of Biomedical Sciences, College of Medicine, University of Illinois, Rockford, Illinois, USA.
Angela L P A SamyDepartment of Biomedical Sciences, College of Medicine, University of Illinois, Rockford, Illinois, USA.
Gnanasekar MunirathinamDepartment of Biomedical Sciences, College of Medicine, University of Illinois, Rockford, Illinois, USA.ORCID https://orcid.org/0000-0002-1445-6311
University of Illinois Chicago, Rockford campus · US

Funding

Van Breemen: Project 3; Botanical Dietary Supplements - Metabolism and Safety in Women (Van Breemen)P50AT000155 · NCCIH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PAULI, GUIDO F · 1999 to 2019
$30.4M
Overcoming EMT-driven metastatic castration-resistant prostate cancerR03CA212890 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MUNIRATHINAM, GNANASEKAR · 2017 to 2018
$160k
Dietary management of castration-resistant prostate cancerR03CA227218 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MUNIRATHINAM, GNANASEKAR · 2018 to 2019
$160k
Targeting TCTP Signaling to Control Castration-Resistant Prostate CancerR03CA230829 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MUNIRATHINAM, GNANASEKAR · 2018 to 2019
$160k
National Institute of Health R03 CA212890-01A1National Institute of Health R03 CA227218National Institute of Health R03 CA230829NCCIH NIH HHS P50 AT000155NCI NIH HHS R03 CA212890NCI NIH HHS R03 CA227218NCI NIH HHS R03 CA230829UIC-NIH Botanical Center Pilot P50 AT 000155
6 · The paper itself

Abstract

Apoptosis and autophagy are important processes that control cellular homeostasis and have been highlighted as promising targets for novel anticancer drugs. This study aims to investigate the inhibitory effects and mechanisms of Neferine (Nef), an alkaloid from the lotus seed embryos of Nelumbo nucifera (N. nucifera), as a dual inducer of apoptosis and autophagy through the reactive oxygen species (ROS) activation in cervical cancer cells. Nef and N. nucifera extract suppressed the cell viability of HeLa and SiHa cells in a dose-dependent manner. Importantly, Nef showed minimal toxicity to normal cells. Furthermore, Nef inhibited anchorage-independent growth, colony formation and migration ability of cervical cancer cells. Nef induces mitochondrial apoptosis by increasing pro-apoptotic protein bax, cytochrome-c, cleaved caspase-3 and caspase-9, poly-ADP ribose polymerase (PARP) cleavage, DNA damage (pH

Indexed as

ApoptosisBenzylisoquinolinesBiological ProductsCell Line, TumorFemaleHeLa CellsHumansLotusSeedsTransfectionTumor Protein, Translationally-Controlled 1Uterine Cervical NeoplasmsBenzylisoquinolinesBiological ProductsneferineTPT1 protein, humanTumor Protein, Translationally-Controlled 1apoptosis and autophagycervical cancerDNA damageNeferinereactive oxygen species

Identifiers

PMID32364634
PMCPMC7511448
OpenAlexW3021424133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.